Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Wuhan YZY Biopharma Co., Ltd. Class H (2496) Stock Price & Analysis

1 Followers

2496 Stock Chart & Stats

HK$4.00HK$0.00(0.00%)
At close: 4:00 PM GMT+8
HK$2.5HK$3HK$3.5Aug 12Aug 24Sep 24Oct 8Oct 20
Day’s Range
HKD 4.00 - HKD 4.00
52-Week Range
HKD 0.96 - HKD 8.50
Previous Close
HKD 4.00
Volume
N/A
Average Volume (3M)
76.30K
Market Cap
HKD 1.05B
Enterprise Value
HKD 809.03M
Total Cash (Recent Filing)
HKD 75.98M
Total Debt (Recent Filing)
HKD 138.62M
Price to Earnings (P/E)
―
Beta
0.19
Next Earnings
Mar 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improved Cash Burn

The sharp reduction in operating and free-cash-flow burn indicates materially tighter spending or working-capital relief. Although the company remains cash-consuming, this improvement could extend its operating runway and provide a better base for restoring financial self-sufficiency.

Reduced Loss Severity

Improvement from the exceptionally severe losses of earlier years suggests some progress in controlling the scale of earnings deterioration. This does not imply profitability, but a less negative trajectory can support future restructuring and improve the potential for operating recovery.

Historical Gross-Margin Capability

The 2024 gross margin demonstrates that the business has previously generated a substantially stronger gross-profit profile. While the subsequent collapse is a major concern, that historical margin level indicates potential operating economics that could matter if revenue quality and product mix recover.

Bears Say

Revenue Contraction

The steep revenue decline signals weakening commercial scale and makes the company’s earnings base less predictable. Persistent top-line contraction can reduce operating leverage, limit reinvestment capacity, and make recovery more dependent on external financing or a successful business turnaround.

Severe Profitability Deterioration

The collapse in gross margin combined with a deeply negative net margin shows that current revenue is not supporting the cost base. This weak profitability is likely to remain a fundamental constraint on internal funding, strategic investment, and the durability of any recovery.

Negative Equity And Higher Debt

Negative shareholders’ equity and materially higher debt indicate substantially weaker solvency and financial flexibility. The deteriorated capital structure can constrain additional borrowing, increase dependence on new capital, and leave the company less able to absorb continued operating losses.

Wuhan YZY Biopharma Co., Ltd. Class H News

2496 FAQ

What was Wuhan YZY Biopharma Co., Ltd. Class H’s price range in the past 12 months?
Wuhan YZY Biopharma Co., Ltd. Class H lowest stock price was HK$0.96 and its highest was HK$8.50 in the past 12 months.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s market cap?
Wuhan YZY Biopharma Co., Ltd. Class H’s market cap is HK$1.05B.
When is Wuhan YZY Biopharma Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Wuhan YZY Biopharma Co., Ltd. Class H’s earnings last quarter?
Wuhan YZY Biopharma Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -HK$0.037 earnings per share for the quarter.
Is Wuhan YZY Biopharma Co., Ltd. Class H overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Wuhan YZY Biopharma Co., Ltd. Class H pay dividends?
Wuhan YZY Biopharma Co., Ltd. Class H does not currently pay dividends.
What is Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate?
Wuhan YZY Biopharma Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wuhan YZY Biopharma Co., Ltd. Class H have?
Wuhan YZY Biopharma Co., Ltd. Class H has 179,479,110 shares outstanding.
What happened to Wuhan YZY Biopharma Co., Ltd. Class H’s price movement after its last earnings report?
Wuhan YZY Biopharma Co., Ltd. Class H reported an EPS of -HK$0.037 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuhan YZY Biopharma Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2496
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology